{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:10:49Z","timestamp":1785352249630,"version":"3.55.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>This study explores the treatment experience of people living with HIV who transitioned from oral ART to long-acting injectable therapy Cabotegravir\/Rilpivirine (LAI-CAB\/RPV) in Puerto Rico. Interpretative Phenomenological Analysis was used to explore the lived experiences of people with HIV 21 years old or older who transitioned from oral ART to LAI-CAB\/RPV. Purposeful sampling was used to recruit study participants. Ten in-depth interviews were conducted at the clinic, audio recorded, and transcribed verbatim. Participants\u2019 mean age was 67 years (\u00b19), most were men (70%), and most identified themselves as heterosexual (60%). On average, they have taken oral ART for 23.2 years\u2009\u00b1\u20098.7. The transition to LAI-CAB\/RPV marked a profound positive change; for them, injectable ART means \u201cfreedom,\u201d improving their quality of life, providing relief, and a sense of \u201cnormalcy.\u201d Adherence remained robust, marked by consistent appointment attendance. They overwhelmingly encouraged others to embrace the transition, highlighting its transformative impact on their lives. Study participants\u2019 positive experiences underscore the potential of LAI-CAB\/RPV to revolutionize the standard of care, enhancing both the treatment experience and the overall well-being of people living with HIV. Continued research is crucial to refine and expand the benefits of this treatment approach.<\/jats:p>","DOI":"10.1371\/journal.pone.0332661","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T17:25:41Z","timestamp":1757957141000},"page":"e0332661","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment experience of people living with HIV who transitioned from oral to long-acting injectable antiretrovirals in Puerto Rico: A qualitative study"],"prefix":"10.1371","volume":"20","author":[{"given":"Robert A.","family":"Velez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7295-7221","authenticated-orcid":true,"given":"Georgina","family":"Silva-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalumi","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-3561","authenticated-orcid":true,"given":"Yarelis","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Badillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"pone.0332661.ref001","unstructured":"HIV.gov. The Global HIV and AIDS Epidemic. Available from: https:\/\/www.hiv.gov\/federal-response\/pepfar-global-aids\/global-hiv-aids-overview"},{"key":"pone.0332661.ref002","unstructured":"Epidemiologia del VIH en Puerto Rico: 2013-2022. https:\/\/www.salud.pr.gov\/CMS\/DOWNLOAD\/8024. 2022."},{"key":"pone.0332661.ref003","unstructured":"Centers for Disease Control and Prevention. CDC Publishes New HIV Surveillance Reports. Available from: https:\/\/www.cdc.gov\/nchhstp\/director-letters\/cdc-publishes-new-hiv-surveillance-reports.html#:~:text=The%20estimated%20number%20of%20new,likely%20contributed%20to%20the%20decline. 2024."},{"issue":"10","key":"pone.0332661.ref004","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11606-009-1068-8","article-title":"The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV\/AIDS","volume":"24","author":"JN Sayles","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"1","key":"pone.0332661.ref005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/ijcm.IJCM_164_20","article-title":"A Qualitative Study to Identify the Perceptions of Adherence to Antiretroviral Therapy among People Living with HIV","volume":"46","author":"AE Paramesha","year":"2021","journal-title":"Indian J Community Med"},{"issue":"10","key":"pone.0332661.ref006","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40266-013-0107-7","article-title":"Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals","volume":"30","author":"L Ghidei","year":"2013","journal-title":"Drugs Aging"},{"key":"pone.0332661.ref007","author":"HIV Surveillance System HIV Prevention Program Ryan White part b\/ADAP Puerto Rico Department of Health"},{"key":"pone.0332661.ref008","unstructured":"Gobierno de Puerto Rico. Strategic Partnerships and Planning to Support Ending the HIV Epidemic in the United States and Other Territories: San Juan, Puerto Rico. 2020. Available from: https:\/\/www.salud.pr.gov\/CMS\/DOWNLOAD\/5846"},{"issue":"7","key":"pone.0332661.ref009","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2105\/AJPH.2021.306342","article-title":"Missed Opportunities for HIV Prevention in Puerto Rico: An Argument for Inclusivity and Community Coalitions","volume":"111","author":"J Lopez-Rios","year":"2021","journal-title":"Am J Public Health"},{"issue":"12","key":"pone.0332661.ref010","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression","volume":"382","author":"S Swindells","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0332661.ref011","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12913-021-06214-9","article-title":"Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials","volume":"21","author":"A Mantsios","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"pone.0332661.ref012","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab439","article-title":"Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 study","volume":"8","author":"GH Smith","year":"2021","journal-title":"Open Forum Infectious Diseases"},{"issue":"12","key":"pone.0332661.ref013","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks","volume":"24","author":"M Murray","year":"2020","journal-title":"AIDS Behav"},{"issue":"1","key":"pone.0332661.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain","volume":"13","author":"D Kerrigan","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"pone.0332661.ref015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/apc.2014.0010","article-title":"Total daily pill burden in HIV-infected patients in the southern United States","volume":"28","author":"S Zhou","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"pone.0332661.ref016","volume-title":"Qualitative evaluation and research methods","author":"MQ Patton","year":"1990","edition":"2"},{"key":"pone.0332661.ref017","doi-asserted-by":"crossref","DOI":"10.1037\/0000259-000","volume-title":"Interpretative Phenomenological Analysis: Theory, Method and Research","author":"AJ Smith","year":"2022","edition":"2"},{"issue":"7","key":"pone.0332661.ref018","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women","volume":"385","author":"RJ Landovitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0332661.ref019","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection","volume":"382","author":"C Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0332661.ref020","unstructured":"European Medicines Agency. First long-acting injectable antiretroviral therapy for HIV recommended for approval. Available from: https:\/\/www.ema.europa.eu\/en\/news\/first-long-acting-injectable-antiretroviral-therapy-hiv-recommended-approval. 2020."},{"key":"pone.0332661.ref021","unstructured":"National Institutes of Health. Long-acting HIV treatment benefits adults with barriers to daily pill taking and adolescents with suppressed HIV. Available from: https:\/\/www.nih.gov\/news-events\/news-releases\/long-acting-hiv-treatment-benefits-adults-barriers-daily-pill-taking-adolescents-suppressed-hiv"},{"key":"pone.0332661.ref022","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/PPA.S251812","article-title":"Patients\u2019 preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire","author":"C Blackwood","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"pone.0332661.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125582","article-title":"A Social-Ecological View of Barriers and Facilitators for HIV Treatment Adherence: Interviews with Puerto Rican HIV Patients","volume":"10","author":"EM Castro","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0332661.ref024","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10461-012-0172-7","article-title":"A proposal for quality standards for measuring medication adherence in research","volume":"17","author":"AB Williams","year":"2013","journal-title":"AIDS Behav"},{"key":"pone.0332661.ref025","unstructured":"World Health Organization. WHO recommends long-acting cabotegravir for HIV prevention. Available from: https:\/\/www.who.int\/news\/item\/28-07-2022-who-recommends-long-acting-cabotegravir-for-hiv-prevention. 2022."},{"issue":"1","key":"pone.0332661.ref026","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting Injectable Cabotegravir\/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy","volume":"78","author":"JB Brock","year":"2024","journal-title":"Clin Infect Dis"},{"key":"pone.0332661.ref027","unstructured":"U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2024."}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T17:25:46Z","timestamp":1757957146000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332661"}},"subtitle":[],"editor":[{"given":"James","family":"Mockridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332661","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}